EYPT Q4 2018 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+161.7% YoY

Gross Profit

-$2M-71.1% margin

Operating Income

-$11M-450.7% margin

Net Income

-$12M-474.8% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

+402.5%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$78M

Total Liabilities

$41M

Stockholders' Equity

$38M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$933,000	+161.7%
Gross Profit	-$2M	-$3M	+47.9%
Operating Income	-$11M	-$6M	-89.5%
Net Income	-$12M	-$6M	-100.5%